000 | 01824 a2200493 4500 | ||
---|---|---|---|
005 | 20250517194557.0 | ||
264 | 0 | _c20190816 | |
008 | 201908s 0 0 eng d | ||
022 | _a1549-4713 | ||
024 | 7 |
_a10.1016/j.ophtha.2017.11.026 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aBrown, David M | |
245 | 0 | 0 |
_aTargeted Retinal Photocoagulation for Diabetic Macular Edema with Peripheral Retinal Nonperfusion: Three-Year Randomized DAVE Trial. _h[electronic resource] |
260 |
_bOphthalmology _c05 2018 |
||
300 |
_a683-690 p. _bdigital |
||
500 | _aPublication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
650 | 0 | 4 | _aAdult |
650 | 0 | 4 | _aAged |
650 | 0 | 4 |
_aAngiogenesis Inhibitors _xtherapeutic use |
650 | 0 | 4 | _aCombined Modality Therapy |
650 | 0 | 4 |
_aDiabetic Retinopathy _xdrug therapy |
650 | 0 | 4 | _aFemale |
650 | 0 | 4 | _aFluorescein Angiography |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 | _aIntravitreal Injections |
650 | 0 | 4 |
_aLaser Coagulation _xmethods |
650 | 0 | 4 |
_aMacular Edema _xdrug therapy |
650 | 0 | 4 | _aMale |
650 | 0 | 4 | _aMiddle Aged |
650 | 0 | 4 | _aProspective Studies |
650 | 0 | 4 |
_aRanibizumab _xtherapeutic use |
650 | 0 | 4 |
_aRetinal Vessels _xphysiopathology |
650 | 0 | 4 | _aRetreatment |
650 | 0 | 4 | _aTomography, Optical Coherence |
650 | 0 | 4 |
_aVascular Endothelial Growth Factor A _xantagonists & inhibitors |
650 | 0 | 4 |
_aVisual Acuity _xphysiology |
700 | 1 | _aOu, William C | |
700 | 1 | _aWong, Tien P | |
700 | 1 | _aKim, Rosa Y | |
700 | 1 | _aCroft, Daniel E | |
700 | 1 | _aWykoff, Charles C | |
773 | 0 |
_tOphthalmology _gvol. 125 _gno. 5 _gp. 683-690 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.ophtha.2017.11.026 _zAvailable from publisher's website |
999 |
_c27982822 _d27982822 |